Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | GRM2 | Q14416 | 18/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199572 | 0.85 | LMNA (0.64) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL4129495 | 0.82 | LMNA (0.60) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL171728 | 0.82 | GRM2 (0.69) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL10460796 | 0.81 | LMNA (0.62) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL1828011 | 0.80 | LMNA (0.57) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL171187 | 0.79 | GRM2 (0.54) | LMNAGRM2 | |
| SCHEMBL1830288 | 0.79 | GRM2 (0.51) | LMNAGRM2 | |
| SCHEMBL16332029 | 0.78 | LMNA (0.59) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL27199458 | 0.78 | LMNA (0.59) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL8160720 | 0.78 | TNF (0.41) | LMNAMAPTCYP2C9GRM2BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20100063092-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063092-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2134701-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134690-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134708-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107479-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063092-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | GRM2, GRIK2, GRIN2C | LMNA 3154/4885MAPT 1909/4885CYP2C9 1599/4885 |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | GRM2, GRM1, GRM3 | LMNA 3832/4885MAPT 2544/4885CYP2C9 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.